February 2, 2026 — Leads & Copy —
Revvity, Inc. (NYSE: RVTY) reported its financial results for the fourth quarter and full year which ended Dec. 28, 2025.
The company reported GAAP earnings per share of $0.87 for the fourth quarter, compared to $0.78 for the same period last year. Revenue for the quarter was $772 million, compared to $729 million for the same period last year. GAAP operating income from continuing operations for the quarter was $112 million, compared to $119 million for the same period last year. GAAP operating profit margin from continuing operations was 14.5% of revenue, compared to 16.3% for the same period last year.
Adjusted earnings per share from continuing operations for the fourth quarter was $1.70, compared to $1.42 for the same period last year. Adjusted operating income was $229 million, compared to $221 million for the same period last year. Adjusted operating profit margin was 29.7% of revenue, compared to 30.3% for the same period last year.
For the full year, the company reported GAAP earnings per share of $2.07 in 2025, compared to $2.20 in 2024. Revenue for the year was $2.856 billion, compared to $2.755 billion in 2024. GAAP operating income from continuing operations for the year was $357 million, compared to $347 million in 2024. GAAP operating profit margin from continuing operations for the year was 12.5% of revenue, compared to 12.6% in 2024.
Adjusted earnings per share from continuing operations for the full year was $5.06, compared to $4.90 in 2024. Adjusted operating income for the year was $773 million, compared to $779 million in 2024. Adjusted operating profit margin for the year was 27.1% of revenue, compared to 28.3% in 2024.
Prahlad Singh, president and chief executive officer of Revvity, said the company finished 2025 strong and delivered results that were ahead of expectations. Singh added that the company’s portfolio transformation over the past few years positions it well to capitalize on improving end market conditions and deliver differentiated results in the years to come.
In the Life Sciences segment, fourth-quarter revenue was $382 million, compared to $375 million in the same period last year. Revenue increased 2%, while organic revenue was flat compared to the same period last year. Full-year revenue was $1.431 billion, compared to $1.399 billion in 2024. Revenue and organic revenue both increased 2% compared to the same period last year. Fourth-quarter adjusted operating income was $136 million, compared to $138 million in the same period last year. Adjusted operating profit margin was 35.6% of revenue, compared to 36.9% for the same period last year. Full-year adjusted operating income was $458 million, compared to $467 million in 2024. Adjusted operating profit margin was 32.0% of revenue, compared to 33.4% in 2024.
In the Diagnostics segment, fourth-quarter revenue was $390 million, compared to $355 million in the same period last year. Revenue increased 10%, and organic revenue increased 7% compared to the same period last year. Full-year revenue was $1.425 billion, compared to $1.356 billion in 2024. Revenue increased 5%, and organic revenue increased 4% compared to the same period last year. Fourth-quarter adjusted operating income was $91 million, compared to $91 million in the same period last year. Adjusted operating profit margin was 23.4% of revenue, compared to 25.7% for the same period last year. Full-year adjusted operating income was $344 million, compared to $354 million in 2024. Adjusted operating profit margin was 24.2% of revenue, compared to 26.1% in 2024.
For the full year 2026, the company forecasts total revenue of $2.96-$2.99 billion, organic revenue growth of 2-3%, and adjusted earnings per share of $5.35-$5.45.
The company will discuss its fourth-quarter and full-year 2025 results and its outlook for business trends during a webcast on February 2, 2026, at 8:00 a.m. Eastern Time. A live audio webcast and presentation will be available on the Investors section of the company’s website, ir.revvity.com.
At Revvity, the company provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. With 2025 revenue of $2.9 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia, and governments. It is part of the S&P 500 index and has customers in more than 160 countries.
Source: Revvity
